Meeder Asset Management Inc. Has $214,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Meeder Asset Management Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 655.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 204 shares of the biopharmaceutical company’s stock after acquiring an additional 177 shares during the quarter. Meeder Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $214,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Brown Lisle Cummings Inc. raised its position in Regeneron Pharmaceuticals by 18.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 10 shares during the last quarter. Sachetta LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the period. Adirondack Trust Co. raised its position in shares of Regeneron Pharmaceuticals by 2.4% during the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 10 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the period. Finally, Western Financial Corp CA boosted its holdings in Regeneron Pharmaceuticals by 0.7% in the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after acquiring an additional 12 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on REGN shares. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Royal Bank of Canada decreased their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Oppenheimer dropped their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Truist Financial cut their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.3 %

Shares of NASDAQ:REGN opened at $744.60 on Wednesday. The business’s 50 day moving average is $969.72 and its 200 day moving average is $1,032.16. Regeneron Pharmaceuticals, Inc. has a 12-month low of $736.19 and a 12-month high of $1,211.20. The stock has a market cap of $81.82 billion, a price-to-earnings ratio of 18.43, a PEG ratio of 2.86 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.